Ascendis Pharma A/S (ASND) Q2 2025 Earnings Call

Investor webinar replay

Watch the replay and follow the connected company analysis, news, and investor updates for Ascendis Pharma A/s.

Watch the replay

Replay transcript excerpt

WEBVTT 00:00:00.000 -- 00:00:05.240 Good day, and thank you for standing by. Welcome to the Q2 2025 Ascendis Pharma Earnings 00:00:05.240 -- 00:00:08.980 Conference call. At this time, all participants are in listen-only mode. 00:00:08.980 -- 00:00:12.580 After the speaker's presentation, there will be a question and answer session. 00:00:12.580 -- 00:00:17.140 To ask a question during the session, you will need to press star 1-1 on your telephone. 00:00:17.140 -- 00:00:20.720 You will then hear an automated message advising that your hand is raised. 00:00:20.720 -- 00:00:23.640 To withdraw your question, please press star 1-1 again. 00:00:23.640 -- 00:00:26.280 You may ask one question and one follow-up. 00:00:26.280 -- 00:00:28.780 Please be advised that today's conference is being recorded. 00:00:28.780 -- 00:00:32.500 I would now like to hand the conference over to your first speaker today, Scott Smith, 00:00:32.500 -- 00:00:36.460 Ascendis Pharma CFO. Please go ahead. 00:00:36.460 -- 00:00:41.780 Manu Tak, operator. And thank you, everyone, for joining our second quarter 2025 financial 00:00:41.780 -- 00:00:45.900 results conference call. I'm Scott Smith, 00:00:45.900 -- 00:00:49.940 executive vice president and chief financial officer at Ascendis Pharma. 00:00:49.940 -- 00:00:54.960 Joining me on today's call are Yen Muller-Mickelson, 00:00:55.640 -- 00:01:00.680 president and chief executive officer, Sherry Glass, chief business officer, 00:01:00.680 -- 00:01:05.000 Jay Wu, executive vice president and president, 00:01:05.000 -- 00:01:10.280 US market, Amy Hsu, executive vice president of Endocrine and Rare Disease 00:01:10.280 -- 00:01:14.200 Medical Sciences, and chief medical officer. 00:01:14.200 -- 00:01:18.600 Before we begin, I would like to remind you ...